Herpes Simplex
A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)
Subtype terms (5)
More specific conditions that are subtypes of Herpes Simplex in the MeSH hierarchy.
- Herpes Genitalis
25 drugs (6 approved, 19 experimental)
- Herpes Labialis
40 drugs (17 approved, 23 experimental)
- Kaposi Varicelliform Eruption
- Keratitis, Herpetic
9 drugs (6 approved, 3 experimental)
- Stomatitis, Herpetic
7 drugs (5 approved, 2 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (1)
Phase 3 trials (7)
Phase 2 trials (10)
Phase 1 trials (9)
Organizations
Organization Involved with Phase 4 Indications (11)
- Gilead Sciences
- CONRAD
- GlaxoSmithKline
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Institutes of Health (NIH)
- University of Pittsburgh
- University of Washington
- New York University
- Radboud University
- Stanley Medical Research Institute
- Ram Manohar Lohia Insitute of Medical Sciences
Organization Involved with Phase 3 Indications (33)
- Novartis
- Glaxo Wellcome
- Medivir
- Maruho Co., Ltd.
- BlueWillow Biologics
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- National Eye Institute (NEI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- CIHR Canadian HIV Trials Network
- University of London
- Integrative Medicine Institute
- Southern Illinois University
- Southwest College of Naturopathic Medicine
- University of Liverpool
- University of New Mexico
- University of Toronto
- Wake Forest University
- Asociación Civil Impacta Salud y Educación, Peru
- Uppsala University
- Icahn School of Medicine at Mount Sinai
- University of the Witwatersrand
- Karolinska Institute
- University of Alabama, Birmingham
- Bill and Melinda Gates Foundation
- Canadian Institutes of Health Research (CIHR)
- United States Agency for International Development
- Follow-on African Consortium for Tenofovir Studies
- Women's Health Services, Santa Fe, New Mexico
- Matrixx Initiatives, Inc.
- +3 more
Organization Involved with Phase 2 Indications (26)
- Oclassen
- AiCuris Anti-infective Cures GmbH
- Beech Tree Labs, Inc.
- Vical
- Yung Shin Pharm. Ind. Co., Ltd.
- Agenus Inc.
- Genocea Biosciences, Inc.
- Population Council
- National Institute on Aging (NIA)
- Umeå University
- Case Western Reserve University
- Changhua Christian Hospital
- China Academy of Chinese Medical Sciences
- Columbia University
- Fudan University
- Umea University
- Medpace, Inc.
- Hill Top Research
- Chiangrai Prachanukroh Hospital
- Norwich Clinical Research Associates Ltd.
- Puget Sound Partners for Global Health
- Comprehensive International Program of Research on AIDS
- Chiang Rai District Health Office
- National Center for Infectious Diseases
- Government of Thailand
- Shanghai BDgene Co., Ltd.
Organization Involved with Phase 1 Indications (14)
Organization Involved with Other Experimental Indications (2)